# Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc. is a company headquartered in Cambridge, MA, United States.

## Company overview

- **Legal name:** Jounce Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Cambridge, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001640455

## About

Jounce Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001640455, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2023-03-10, it reported net income of USD -50,919,000; total assets of USD 212,550,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Net income:** -$50.9M (USD -50,919,000)
- **Total assets:** $212.6M (USD 212,550,000)
- **Cash and equivalents:** $150.6M (USD 150,572,000)
- **Operating cash flow:** -$28.9M (USD -28,877,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$90.9M (USD -90,872,000)
- **Total assets:** $252.7M (USD 252,696,000)
- **Cash and equivalents:** $95.5M (USD 95,529,000)
- **Operating cash flow:** -$83.5M (USD -83,494,000)

### FY2020 (period ended 2020-12-31)

- **Net income:** -$43.8M (USD -43,842,000)
- **Total assets:** $244.2M (USD 244,236,000)
- **Cash and equivalents:** $147.5M (USD 147,493,000)
- **Operating cash flow:** -$27.8M (USD -27,788,000)

### FY2019 (period ended 2019-12-31)

- **Net income:** $56.8M (USD 56,823,000)
- **Total assets:** $205.9M (USD 205,882,000)
- **Cash and equivalents:** $53.2M (USD 53,241,000)
- **Operating cash flow:** -$30.1M (USD -30,129,000)

## Recent SEC filings

- Form SC 13G — filed 2024-02-09
- Form 8-K — filed 2023-05-04 — period 2023-05-02 — 8-K
- Form 10-K/A — filed 2023-04-28 — period 2022-12-31 — 10-K/A
- Form SC 13G — filed 2023-04-12
- Form 8-K — filed 2023-03-30 — period 2023-03-26 — 8-K
- Form 8-K — filed 2023-03-27 — period 2023-03-26 — 8-K
- Form 8-K — filed 2023-03-15 — period 2023-03-14 — 8-K
- Form SC 13D — filed 2023-03-14
- Form 8-K — filed 2023-03-13 — period 2023-03-10 — 8-K
- Form 10-K — filed 2023-03-10 — period 2022-12-31 — 10-K
- Form SC 13G — filed 2023-03-06
- Form 8-K — filed 2023-02-23 — period 2023-02-22 — 8-K

---

Updated: 2026-10-23T20:10:52Z

Canonical page: https://altss.com/profile/jounce-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology